Claro Advisors’s First Trust Nasdaq Pharmaceuticals ETF FTXH Stock Holding History

Claro Advisors’s Portfolio FTXH Stock Details FTXH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-84	Closed	-$2K	–	447
2018 Q4	$2K	Buy	+84	New	+$1.81K	﹤0.01%	916

Other funds holding FTXH

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

SMFS

Squar Milner Financial Services Irvine, California $176M AUM 10.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Claro Advisors's FTXH Position: Q1 2019 in Review

Claro Advisors sold out of First Trust Nasdaq Pharmaceuticals ETF (FTXH) in Q1 2019, closing a stake of 84 shares — an estimated $2K sold.

Claro Advisors first reported a position in FTXH in Q4 2018 and held it in 1 quarter. The position peaked at $2K in Q4 2018. 8 funds tracked by Wall St. Rank hold FTXH as of Q1 2019.

Claro Advisors reported no remaining First Trust Nasdaq Pharmaceuticals ETF position as of Q1 2019 after selling out during the quarter.
Claro Advisors sold 84 First Trust Nasdaq Pharmaceuticals ETF shares in Q1 2019, an estimated $2K.
Claro Advisors first reported a position in First Trust Nasdaq Pharmaceuticals ETF in Q4 2018 and held it in 1 quarter.
Claro Advisors's First Trust Nasdaq Pharmaceuticals ETF position peaked at $2K in Q4 2018.
8 funds tracked by Wall St. Rank held First Trust Nasdaq Pharmaceuticals ETF as of Q1 2019.

Based on Claro Advisors's 13F filing for Q1 2019, filed 10 May 2019.